Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.06
VSCI's Cash to Debt is ranked lower than
57% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. VSCI: 0.06 )
VSCI' s 10-Year Cash to Debt Range
Min: 0.05   Max: 22796
Current: 0.06

0.05
22796
Equity to Asset -1.66
VSCI's Equity to Asset is ranked lower than
58% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. VSCI: -1.66 )
VSCI' s 10-Year Equity to Asset Range
Min: -1.76   Max: 0.93
Current: -1.66

-1.76
0.93
F-Score: 3
Z-Score: -14.44
M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -39.73
VSCI's Operating margin (%) is ranked higher than
56% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. VSCI: -39.73 )
VSCI' s 10-Year Operating margin (%) Range
Min: -158.06   Max: -16.27
Current: -39.73

-158.06
-16.27
Net-margin (%) -42.09
VSCI's Net-margin (%) is ranked higher than
56% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. VSCI: -42.09 )
VSCI' s 10-Year Net-margin (%) Range
Min: -151.61   Max: 212
Current: -42.09

-151.61
212
ROA (%) -69.02
VSCI's ROA (%) is ranked higher than
51% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. VSCI: -69.02 )
VSCI' s 10-Year ROA (%) Range
Min: -88.06   Max: 90.36
Current: -69.02

-88.06
90.36
ROC (Joel Greenblatt) (%) -111.66
VSCI's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. VSCI: -111.66 )
VSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -478.99   Max: -94.97
Current: -111.66

-478.99
-94.97
Revenue Growth (3Y)(%) 9.70
VSCI's Revenue Growth (3Y)(%) is ranked higher than
84% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. VSCI: 9.70 )
VSCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 10.1
Current: 9.7

0
10.1
EBITDA Growth (3Y)(%) -18.80
VSCI's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. VSCI: -18.80 )
VSCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 54.9
Current: -18.8

0
54.9
EPS Growth (3Y)(%) -18.10
VSCI's EPS Growth (3Y)(%) is ranked higher than
66% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. VSCI: -18.10 )
VSCI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 48.1
Current: -18.1

0
48.1
» VSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VSCI Guru Trades in Q1 2014

Jim Simons 67,700 sh (-3.29%)
» More
Q2 2014

VSCI Guru Trades in Q2 2014

Jim Simons 53,300 sh (-21.27%)
» More
Q3 2014

VSCI Guru Trades in Q3 2014

Jim Simons 48,100 sh (-9.76%)
» More
Q4 2014

VSCI Guru Trades in Q4 2014

Jim Simons 50,700 sh (+5.41%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.91
VSCI's P/S is ranked higher than
86% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. VSCI: 0.91 )
VSCI' s 10-Year P/S Range
Min: 1   Max: 21.25
Current: 0.91

1
21.25
EV-to-EBIT -6.55
VSCI's EV-to-EBIT is ranked higher than
52% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 73.27 vs. VSCI: -6.55 )
VSCI' s 10-Year EV-to-EBIT Range
Min: -35   Max: -1.6
Current: -6.55

-35
-1.6
Current Ratio 2.70
VSCI's Current Ratio is ranked higher than
72% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. VSCI: 2.70 )
VSCI' s 10-Year Current Ratio Range
Min: 1.26   Max: 13.88
Current: 2.7

1.26
13.88
Quick Ratio 1.58
VSCI's Quick Ratio is ranked higher than
66% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. VSCI: 1.58 )
VSCI' s 10-Year Quick Ratio Range
Min: 0.42   Max: 12.55
Current: 1.58

0.42
12.55
Days Inventory 129.20
VSCI's Days Inventory is ranked higher than
77% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. VSCI: 129.20 )
VSCI' s 10-Year Days Inventory Range
Min: 40.91   Max: 234.92
Current: 129.2

40.91
234.92
Days Sales Outstanding 83.34
VSCI's Days Sales Outstanding is ranked higher than
69% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. VSCI: 83.34 )
VSCI' s 10-Year Days Sales Outstanding Range
Min: 35.77   Max: 86.53
Current: 83.34

35.77
86.53

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.20
VSCI's Price/Median PS Value is ranked higher than
99% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. VSCI: 0.20 )
VSCI' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.96
Current: 0.2

0.38
2.96
Earnings Yield (Greenblatt) -19.30
VSCI's Earnings Yield (Greenblatt) is ranked lower than
51% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. VSCI: -19.30 )
VSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -19.3   Max: 0
Current: -19.3

-19.3
0

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Vision-Sciences Inc was incorporated in Delaware, and are the successor to operations originally begun in 1987. The Company designs, develops, manufactures, and markets products for endoscopy. Its products include flexible endoscope and borescopes. Its segments include medical and industrial. Its medical segment designs, manufactures and sells endoscopy-based products, including its flexible endoscopes, and its EndoSheath technology referred to as a sheath or EndoSheath disposable, for a variety of specialties and markets. Its industrial segment, through its wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers or a small camera for the visual inspection of narrow cavities. Its borescopes are used to inspect aircraft engines, cast parts and ground turbines, among other items. The Companys products are sold throughout the world through direct sales representatives in the United States (U.S.) and independent distributors for the rest of the world. The Company owns the registered trademarks Vision Sciences, Slide-On, EndoSheath, EndoWipe and The Vision System. Its competitors include Olympus, Lenox, Pentax, and Karl Storz. Its operations are regulated under various federal, state, and local laws governing the environment, including laws governing the discharge of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the clean-up of contaminated sites.
» More Articles for VSCI

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 09 2011 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 10 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Aug 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 13 2009 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 14 2009 

More From Other Websites
COGENTIX MEDICAL INC /DE/ Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Mar 31 2015
Uroplasty and Vision-Sciences Complete Merger Mar 31 2015
Uroplasty and Vision-Sciences Complete Merger Mar 31 2015
Vision-Sciences, Inc. Announces 1:5 Reverse Stock Split Mar 31 2015
Vision-Sciences, Inc. Announces 1:5 Reverse Stock Split Mar 31 2015
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement Mar 30 2015
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement Mar 30 2015
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement Mar 30 2015
Uroplasty to Host Investor Meeting at Corporate Headquarters Mar 09 2015
VISION SCIENCES INC /DE/ Financials Feb 19 2015
10-Q for Vision-Sciences, Inc. Feb 14 2015
VISION SCIENCES INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 13 2015
VISION SCIENCES INC /DE/ Files SEC form 10-Q, Quarterly Report Feb 12 2015
VISION SCIENCES INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 06 2015
VISION SCIENCES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 04 2015
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015 Feb 04 2015
Vision-Sciences Reports Financial Results for Third Quarter and First Nine Months of Fiscal 2015 Feb 04 2015
Q3 2015 Vision Sciences Inc Earnings Release - After Market Close Feb 04 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of... Feb 02 2015
Vision-Sciences to Host Third Quarter Fiscal 2015 Results Call Jan 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK